Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis

Baur, B; Oroszlan, M; Hess, O; Carrel, T; Mohacsi, P (2011). Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis. Transplantation proceedings, 43(5), pp. 1853-61. New York, N.Y.: Elsevier 10.1016/j.transproceed.2011.01.174

Full text not available from this repository. (Request a copy)

Since its introduction as an immunosuppressant in the late 1990s, sirolimus (SRL) has been used to prevent rejections after heart transplantation (HTx) in the United States. An analogue, everolimus (ERL) has been mainly used in Europe. We performed a retrospective longitudinal single-center study to evaluate efficacy and side effects of SRL and ERL.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiovascular Surgery

UniBE Contributor:

Hess, Otto; Carrel, Thierry and Mohacsi, Paul

ISSN:

0041-1345

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:20

Last Modified:

06 Dec 2013 13:27

Publisher DOI:

10.1016/j.transproceed.2011.01.174

PubMed ID:

21693289

Web of Science ID:

000292279800086

URI:

https://boris.unibe.ch/id/eprint/6606 (FactScience: 211602)

Actions (login required)

Edit item Edit item
Provide Feedback